Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Brain Res Mol Brain Res ; 114(2): 132-9, 2003 Jun 10.
Article in English | MEDLINE | ID: mdl-12829323

ABSTRACT

This study was designed to evaluate the neuroprotective effect of the cannabinoid agonist WIN-55212 after inducing acute severe asphyxia in newborn rats. The left common carotid artery was ligated in anaesthetised 7-day-old Wistar rats, which were then asphyxiated by inhaling 100% nitrogen for 10 min. Pups recovering from asphyxia were s.c. administered vehicle (n=23), WIN-55212 (0.1 mg/kg, n=18), or WIN-55212 plus the CB1 receptor antagonist SR141716 (3 mg/kg, n=10). Pups undergoing a sham operation served as controls (n=12). Coronal sections of the brain were obtained on the 14th day after surgery and observed under light microscope after Nissl or Fluoro-Jade B (FJB) staining, to respectively quantify surviving or degenerating neurones in the CA1 area of the hippocampus and parietal cortex. Acute asphyxia led to early neurone loss amounting to 19% in the hippocampus and 29% in the cortex (both ANOVA P<0.05 vs. control). Delayed neurone loss occurred in the proportions 13% in the hippocampus and 20% in the cortex (both ANOVA P<0.05 vs. control). Neuronal loss was fully prevented by WIN-55212 administration. Co-administration of SR141716 failed to modify the protective effect of WIN-55212 on early neuronal death, but abolished the WIN-55212-induced prevention of delayed neuronal death. We conclude that when administered after acute severe asphyxia in newborn rats, WIN-55212 shows a neuroprotective effect, reducing both early and delayed neurone loss. This effect is achieved through two parallel CB1-dependent and -independent mechanisms.


Subject(s)
Asphyxia Neonatorum/drug therapy , Cannabinoids/pharmacology , Hypoxia-Ischemia, Brain/drug therapy , Morpholines/pharmacology , Naphthalenes/pharmacology , Nerve Degeneration/drug therapy , Neuroprotective Agents/pharmacology , Receptors, Drug/drug effects , Animals , Animals, Newborn , Asphyxia Neonatorum/metabolism , Asphyxia Neonatorum/physiopathology , Benzoxazines , Body Weight/drug effects , Body Weight/physiology , Brain/drug effects , Brain/metabolism , Brain/physiopathology , Cannabinoids/therapeutic use , Disease Models, Animal , Female , Humans , Hypoxia-Ischemia, Brain/metabolism , Hypoxia-Ischemia, Brain/physiopathology , Infant, Newborn , Male , Morpholines/therapeutic use , Naphthalenes/therapeutic use , Nerve Degeneration/metabolism , Nerve Degeneration/physiopathology , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/therapeutic use , Piperidines/pharmacology , Pyrazoles/pharmacology , Rats , Rats, Wistar , Receptors, Cannabinoid , Receptors, Drug/metabolism , Rimonabant
SELECTION OF CITATIONS
SEARCH DETAIL
...